CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
10 12 2021
Historique:
received: 01 11 2021
revised: 02 12 2021
accepted: 07 12 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 6 1 2022
Statut: epublish

Résumé

Heparanase is an endo-β-glucuronidase that is best known for its pro-cancerous effects but is also implicated in the pathogenesis of various viruses. Activation of heparanase is a common strategy to increase viral spread and trigger the subsequent inflammatory cascade. Using a Single Nucleotide Polymorphisms (SNP)-associated approach we identified enhancer and insulator regions that regulate HPSE expression. Although a role for heparanase in viral infection has been noticed, the impact of HPSE functional SNPs has not been determined. We investigated the effect of cytomegalovirus (CMV) serostatus on the involvement of HPSE enhancer and insulator functional SNPs in the risk of acute graft versus host disease (GVHD) and granulocyte-colony stimulating factor related CD34

Identifiants

pubmed: 34943994
pii: cells10123489
doi: 10.3390/cells10123489
pmc: PMC8700738
pii:
doi:

Substances chimiques

Antigens, CD34 0
Granulocyte Colony-Stimulating Factor 143011-72-7
heparanase EC 3.2.1.-
Glucuronidase EC 3.2.1.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Israel Science Foundation
ID : grant 1021/19
Organisme : Israel Cancer Research Fund
ID : no
Organisme : the DKFZ-MOST cancer research program
ID : no

Références

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14223-8
pubmed: 14623981
Int J Cancer. 2013 Nov 15;133(10):2351-61
pubmed: 23661597
Viruses. 2015 May 22;7(5):2592-617
pubmed: 26008702
Papillomavirus Res. 2019 Jun;7:188-192
pubmed: 30981651
Curr Opin Oncol. 2013 Nov;25(6):682-8
pubmed: 24097102
J Virol. 2014 Jul;88(13):7389-401
pubmed: 24741094
Biol Blood Marrow Transplant. 2010 Sep;16(9):1309-14
pubmed: 20353832
Front Cell Infect Microbiol. 2018 May 25;8:177
pubmed: 29888215
Rev Med Virol. 2006 May-Jun;16(3):167-86
pubmed: 16710837
Medicine (Baltimore). 2018 Jan;97(4):e9685
pubmed: 29369188
Chem Rec. 2021 Nov;21(11):3087-3101
pubmed: 34145723
Curr Opin Virol. 2019 Aug;37:37-43
pubmed: 31177014
Virus Res. 2011 May;157(2):193-203
pubmed: 21036194
Virology. 1993 Apr;193(2):834-41
pubmed: 8384757
Front Microbiol. 2016 May 13;7:715
pubmed: 27242736
Virology. 2019 Mar;529:1-6
pubmed: 30622027
J Leukoc Biol. 2014 Apr;95(4):677-88
pubmed: 24319286
Oncogenesis. 2018 Jun 29;7(6):51
pubmed: 29955035
Front Immunol. 2013 Nov 20;4:385
pubmed: 24312095
Front Immunol. 2020 Oct 06;11:575047
pubmed: 33123154
Pathogens. 2017 Sep 18;6(3):
pubmed: 28927006
Cells. 2021 Sep 23;10(10):
pubmed: 34685503
J Gen Virol. 2015 Aug;96(8):2232-2241
pubmed: 26289843
Oncotarget. 2019 Jul 02;10(42):4333-4347
pubmed: 31303966
Virol J. 2011 Oct 27;8:485
pubmed: 22032643
Theranostics. 2014 Jan 23;4(3):280-9
pubmed: 24505236
Cancer Lett. 2018 Apr 28;420:182-189
pubmed: 29410005
PLoS Pathog. 2021 Aug 5;17(8):e1009803
pubmed: 34352038
Methods Mol Biol. 2007;379:15-34
pubmed: 17502668
Transl Oncol. 2014 Dec;7(6):732-40
pubmed: 25500083
J Virol. 2015 Apr;89(7):3846-58
pubmed: 25609801
Cell Rep. 2017 Jul 11;20(2):439-450
pubmed: 28700944
J Clin Virol. 2013 May;57(1):36-42
pubmed: 23391370
Front Microbiol. 2019 May 28;10:1186
pubmed: 31191499
Hepatology. 2000 Nov;32(5):1069-77
pubmed: 11050058
Nat Commun. 2015 Apr 27;6:6985
pubmed: 25912399
J Virol. 2017 Jul 12;91(15):
pubmed: 28490587
Adv Exp Med Biol. 2020;1221:759-770
pubmed: 32274736
J Urol. 2003 Sep;170(3):998-1002
pubmed: 12913758
Cell Mol Life Sci. 2020 Dec;77(24):5059-5077
pubmed: 32462405
Blood. 2010 Mar 18;115(11):2319-28
pubmed: 20075159
J Virol. 2020 Feb 28;94(6):
pubmed: 31827001
Adv Exp Med Biol. 2020;1221:3-59
pubmed: 32274705
Virus Res. 1998 Feb;53(2):197-207
pubmed: 9620211
Front Cell Infect Microbiol. 2020 Mar 31;10:130
pubmed: 32296651

Auteurs

Olga Ostrovsky (O)

Chaim Sheba Medical Center, Department of Hematology and Bone Marrow Transplantation, Tel-Hashomer, Ramat Gan 5266202, Israel.

Katia Beider (K)

Chaim Sheba Medical Center, Department of Hematology and Bone Marrow Transplantation, Tel-Hashomer, Ramat Gan 5266202, Israel.

Yan Morgulis (Y)

Chaim Sheba Medical Center, Department of Hematology and Bone Marrow Transplantation, Tel-Hashomer, Ramat Gan 5266202, Israel.

Nira Bloom (N)

Chaim Sheba Medical Center, Department of Hematology and Bone Marrow Transplantation, Tel-Hashomer, Ramat Gan 5266202, Israel.

Angel Cid-Arregui (A)

German Cancer Research Center, D-69120 Heidelberg, Germany.

Avichai Shimoni (A)

Chaim Sheba Medical Center, Department of Hematology and Bone Marrow Transplantation, Tel-Hashomer, Ramat Gan 5266202, Israel.

Israel Vlodavsky (I)

Technion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa 3525433, Israel.

Arnon Nagler (A)

Chaim Sheba Medical Center, Department of Hematology and Bone Marrow Transplantation, Tel-Hashomer, Ramat Gan 5266202, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH